Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These.
No Clinical, Biochemical Changes Observed After Switch to Adalimumab Biosimilar for IBD hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn s disease. That is the belief of Maria Belvisi at AstraZeneca.